According to GuruFocus Insider Data, the top recent CFO buys were: Christopher & Banks Corp. (CBK, Financial), Actuant Corp. (ATU, Financial) and Catalyst Biosciences Inc. (CBIO, Financial).
Christopher & Banks: EVP, COO and CFO Peter G. Michielutti bought 30,000 shares
On Dec. 16, EVP, COO and CFO Peter G. Michielutti bought 30,000 shares at an average price of $1.1. The price of the stock has increased by 39.09%. Christopher & Banks has a market cap of $56.97 million, and its shares were traded at around $1.53. The company has a P/E ratio of 2.00 and P/S ratio of 0.15. Over the past five years, Christopher & Banks had an annual average earnings growth of 1.60%.
Christopher & Banks announced its 2015 fourth-quarter results with revenues of $103.64 million and gross profit of $37.12 million; the net loss was $315,000. The 2015 total revenue was $418.58 million, a 4% decrease from the 2014 total revenue. The 2015 gross profit was $147.79 million, a 2% decrease from the 2014 gross profit. The 2015 net income was $47.13 million.
On Dec. 16, President and CEO Luann Via bought 100,000 shares at an average price of $1.11. The price of the stock has increased by 37.84%. On Dec. 21, Director Patricia Stensrud bought 1,000 shares at an average price of $1.27. The price of the stock has increased by 20.47%. On Dec. 17, Director Anne L. Jones bought 10,000 shares at an average price of $1.19. The price of the stock has increased by 28.57%.
Actuant: Executive Vice President - CFO Andrew Lampereur bought 20,000 shares
On Dec. 22, Executive Vice President - CFO Andrew Lampereur bought 20,000 shares at an average price of $23.12. The price of the stock has increased by 7.14%. Actuant has a market cap of $1.48 billion, and its shares were traded at around $24.77. The company has a P/E ratio of 79.10 and P/S ratio of 1.24 with a dividend yield of 0.16%.
Actuant announced its 2015 third-quarter results with revenues of $300.38 million and gross profit of $106.54 million; the net income was $22.08 million. The 2015 total revenue was $1.25 billion, an 11% decrease from the 2014 total revenue. The 2015 gross profit was $461.84 million, a 16% decrease from the 2014 gross profit. The 2015 net income was $19.87 million.
On Dec. 23, President and CEO Robert C. Arzbaecher bought 210,000 shares at an average price of $23.71. The price of the stock has increased by 4.47%. On Dec. 22, EVP-Human Resources Eugene Edward Skogg bought 5,000 shares at an average price of $23.68. The price of the stock has increased by 4.6%. On Oct. 30, VP Business Development Ted Wozniak bought 5,300 shares at an average price of $22.63. The price of the stock has increased by 9.46%.
Catalyst Biosciences: CFO Fletcher Payne bought 10,000 shares
On Dec. 17, CFO Fletcher Payne bought 10,000 shares at an average price of $2. The price of the stock has increased by 30.5%. Catalyst Biosciences has a market cap of $29.83 million and its shares were traded at around $2.61. The company has a dividend yield of 152.66%.
Catalyst Biosciences announced its 2015 third-quarter results with revenues and gross profit of $1.58 million; the net income was $1.46 million. The 2014 total revenue and gross profit was $275,000, a 92% decrease from the 2013 total revenue and gross profit. The 2014 net income was $32.62 million.
On Dec. 17, President and CEO Nassim Usman bought 4,000 shares at an average price of $2. The price of the stock has increased by 30.5%. On Dec. 17, Director Stephen A. Hill bought 5,000 shares at an average price of $2.03. The price of the stock has increased by 28.57%.
